Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$6.1B

Dec1Thu

Pre-Earnings Brief

UpcomingQ2-2024After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, its work is particularly relevant as the demand for advanced cancer therapies continues to grow.

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health this quarter.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In Q1-2024, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, resulting in a positive surprise of 44.44%. However, the stock fell by 0.62% the following day, indicating mixed market sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and the potential for positive surprises. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Legend Biotech can continue to beat EPS estimates, it may signal strong operational efficiency and market demand for its therapies, potentially leading to a significant stock price increase.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is crucial for assessing the company's market position and demand for its products, which could significantly impact investor sentiment.

Will management provide any guidance on future product developments?

Insights into future product pipelines could influence investor confidence and expectations for long-term growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Legend Biotech's potential for revenue growth based on recent product developments and industry trends.

Supporting Evidence

The company's recent performance shows a consistent ability to surprise on EPS, which could translate to revenue growth.

Options pricing suggests a significant expected move, indicating that traders are anticipating a noteworthy announcement.

Key Risk

If revenue growth significantly exceeds expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to demonstrate growth and future potential in a competitive biotechnology landscape.

Bull Confirmed If

A revenue growth rate of over 20% would confirm the bull case, indicating strong market demand.

Bear Confirmed If

If revenue growth is below 5%, it could confirm the bear case, suggesting weak market performance.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats estimates and raises guidance, history suggests the stock could rise by an average of 1.71% on the next trading day.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

Should the company miss expectations, history suggests a potential decline of around 6.91% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Management's commentary on market demand for current therapies.
3Insights into competitive positioning within the biotechnology sector.
4Future guidance on revenue expectations for the upcoming quarters.
5Any strategic partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health this quarter.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Legend Biotech can continue to beat EPS estimates, it may signal strong operational efficiency and market demand for its therapies, potentially leading to a significant stock price increase.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is crucial for assessing the company's market position and demand for its products, which could significantly impact investor sentiment.

Will management provide any guidance on future product developments?

Insights into future product pipelines could influence investor confidence and expectations for long-term growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Legend Biotech's potential for revenue growth based on recent product developments and industry trends.

Supporting Evidence

The company's recent performance shows a consistent ability to surprise on EPS, which could translate to revenue growth.

Options pricing suggests a significant expected move, indicating that traders are anticipating a noteworthy announcement.

Key Risk

If revenue growth significantly exceeds expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to demonstrate growth and future potential in a competitive biotechnology landscape.

Bull Confirmed If

A revenue growth rate of over 20% would confirm the bull case, indicating strong market demand.

Bear Confirmed If

If revenue growth is below 5%, it could confirm the bear case, suggesting weak market performance.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats estimates and raises guidance, history suggests the stock could rise by an average of 1.71% on the next trading day.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

Should the company miss expectations, history suggests a potential decline of around 6.91% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Management's commentary on market demand for current therapies.
3Insights into competitive positioning within the biotechnology sector.
4Future guidance on revenue expectations for the upcoming quarters.
5Any strategic partnerships or collaborations that could enhance growth.